Furthermore, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial, a randomized controlled trial that evaluates the CV benefit of a once-weekly injection of semaglutide in patients with overweight or obesity but without T2DM, will lead to a more comprehensive interpretation of incretins’ CV effects, unattached to the metabolic improvement in patients with T2DM, which can represent a major confounding factor [41]. Here, GCG is linked to obesity disorder.